Abstract | PURPOSE: MATERIALS AND METHODS: Patients >65 years with carcinoma of the thoracic esophagus or gastroesophageal junction who were not eligible for platinum-based treatment received erlotinib daily for 1 year starting on day 1 of radiotherapy [50.4 Gy days 1-28 (Mon-Fri) at 1.8 Gy per fraction]. Response was assessed by endoscopy and computed tomography. The primary endpoint was overall survival (OS), and secondary endpoints were complete response, progression-free survival (PFS) and toxicity. RESULTS: The ECOG performance status in the 17 study patients was 0,1 and 2 in 2, 12 and 3 patients, respectively; 1, 5, 7 and 4 patients were in stage I, II, III and IV, respectively; adenocarcinoma was noted in 16 patients and squamous cell carcinoma in 1; there were 3 current, 12 past and 2 never smokers. Median OS was 7.3 months (95% confidence interval, CI: 3.8-22.3) with 14 deaths. There were 2 mucosal complete responses, 1 residual carcinoma in situ and 3 partial endoscopic responses in 9 patients who had endoscopy after radiotherapy. Estimated PFS was 4.5 months (95% CI: 2.4-7.3). Progression was distant (n = 3), locoregional (n = 6), unknown (n = 5) and too early (n = 3). Estimated 1-year survival was 29% (95% CI: 11-51%), 5 patients lived >12 months. Treatment-related toxicities of grade 3-4 occurred in 5 patients. Patients with epidermal growth factor receptor amplification and never smokers had the longest OS (22.3 and 16.6 months, respectively). CONCLUSIONS:
|
Authors | Renuka Iyer, Ravi Chhatrala, Tracey Shefter, Gary Yang, Usha Malhotra, Wei Tan, Charles Levea, Melissa Robins, Nikhil Khushalani |
Journal | Oncology
(Oncology)
Vol. 85
Issue 1
Pg. 53-8
( 2013)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 23860007
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Copyright | Copyright © 2013 S. Karger AG, Basel. |
Chemical References |
- Quinazolines
- Erlotinib Hydrochloride
- ErbB Receptors
|
Topics |
- Adenocarcinoma
(drug therapy, pathology, radiotherapy)
- Aged
- Aged, 80 and over
- Carcinoma, Squamous Cell
(drug therapy, pathology, radiotherapy)
- Chemoradiotherapy
(methods)
- Chemotherapy, Adjuvant
(methods)
- Disease-Free Survival
- ErbB Receptors
(metabolism)
- Erlotinib Hydrochloride
- Esophageal Neoplasms
(drug therapy, pathology, radiotherapy)
- Esophagogastric Junction
(drug effects, pathology, radiation effects)
- Female
- Humans
- Male
- Prospective Studies
- Quinazolines
(therapeutic use)
- Thoracic Duct
(drug effects, pathology, radiation effects)
|